Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG) is a pioneering American corporation headquartered in Sunnyvale, California. The company specializes in the development, manufacturing, and marketing of advanced robotic products that enhance clinical outcomes through minimally invasive surgical techniques. The cornerstone of Intuitive Surgical's innovation is the da Vinci Surgical System, a state-of-the-art robotic platform designed to facilitate complex surgeries with precision and control.
Intuitive Surgical's mission is to transform the surgical experience by providing surgeons with innovative tools that enable better patient outcomes. The da Vinci Surgical System offers a highly magnified, three-dimensional view and robotic assistance, helping surgeons perform precise dissections and reconstructions deep within the body. The system includes several models, including the multiport da Vinci X and Xi and the single-port da Vinci SP, giving hospitals and surgeons versatile options tailored to their needs.
The company has successfully installed over 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 of these installations in the United States alone. The growing presence of these systems in emerging markets underscores the global demand for cutting-edge surgical technology.
In recent news, Intuitive Surgical announced the FDA clearance of its latest generation system, the da Vinci 5, which builds on over a decade of research and offers more than 150 enhancements. This new system aims to improve patient outcomes further, enhance the surgical experience, and reduce overall healthcare costs. Initial deployment of the da Vinci 5 will be limited to select U.S. hospitals with mature robotic surgery programs, before a broader commercial launch.
Intuitive's financial performance remains robust, as highlighted in its recent quarterly reports. The company continues to experience growth in revenue and market penetration, driven by the increasing adoption of robotic-assisted surgery. Its strategic partnerships and collaborations further solidify its market leadership and commitment to innovation.
Intuitive Surgical also emphasizes continuous learning and support for surgical teams, offering comprehensive training programs and educational resources to ensure optimal use of its technologies. The company's dedication to advancing healthcare is reflected in its robust research and development initiatives, aimed at expanding the capabilities and applications of robotic-assisted surgery.
For more detailed financial and operational updates, please visit Intuitive Surgical's official website at www.intuitive.com.
Intuitive (ISRG) reported strong Q4 2024 financial results with revenue reaching $2.41 billion, up 25% from Q4 2023. The company's worldwide da Vinci procedures grew 18% year-over-year, while system placements increased to 493 units, including 174 da Vinci 5 systems. The installed base expanded to 9,902 systems, marking a 15% increase from the previous year.
GAAP net income rose to $686 million ($1.88 per diluted share), compared to $606 million ($1.69 per diluted share) in Q4 2023. Non-GAAP net income reached $805 million ($2.21 per diluted share). The company ended Q4 with $8.83 billion in cash and investments.
For 2025 outlook, Intuitive expects worldwide da Vinci procedures to grow 13-16%, with non-GAAP gross profit margin projected between 67-68% and operating expense growth of 10-15%.
Intuitive (NASDAQ:ISRG) has announced plans to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino through the acquisition of da Vinci and Ion distribution businesses in these regions. The company has entered into agreements with current distributors ab medica, Abex, Excelencia Robotica, and their affiliates.
The transaction is subject to regulatory approvals and is expected to close in 2026. Upon closure, the distribution businesses will be fully integrated into Intuitive's European commercial and marketing organization, led by Senior VP and General Manager Dirk Barten. The move aims to deepen understanding of customer needs and expand access to minimally invasive care in these markets.
Intuitive (ISRG) reported strong preliminary Q4 and full-year 2024 results. Q4 revenue reached $2.41 billion, up 25% year-over-year, while full-year 2024 revenue grew 17% to $8.35 billion. The company placed 493 da Vinci surgical systems in Q4 2024, including 174 da Vinci 5 systems, marking a 19% increase from Q4 2023.
Worldwide da Vinci procedures grew approximately 18% in Q4 and 17% for the full year 2024, reaching approximately 2,683,000 procedures. Growth was driven by a 19% increase in U.S. general surgery procedures and 23% growth in procedures outside the U.S. The company projects worldwide da Vinci procedures to increase 13-16% in 2025.
Q4 instruments and accessories revenue increased 23% to $1.41 billion, while systems revenue grew 36% to $655 million. The company noted no significant COVID-19 disruptions during 2024.
Intuitive (NASDAQ:ISRG) announced three executive leadership promotions to support its global growth strategy. Henry Charlton has been promoted to Executive Vice President and Chief Commercial and Marketing Officer, bringing 21 years of experience across various leadership roles. Gary Loeb has been elevated to Executive Vice President and Chief Legal and Compliance Officer, having joined in 2022 as SVP and General Counsel. Jamie Samath has been promoted to Executive Vice President, Chief Financial Officer and Enterprise Technology Leader, expanding his role since joining in 2013.
These promotions aim to strengthen Intuitive's leadership team as it continues its mission in advancing minimally invasive care. The company, which pioneered robotic-assisted surgery with its da Vinci system, has facilitated over 15 million procedures globally and trained more than 76,000 surgeons worldwide.
A comprehensive meta-analysis published in Annals of Surgery has demonstrated significant benefits of da Vinci robotic surgery compared to laparoscopic and open surgical approaches. The study analyzed 230 studies from 22 countries over 12 years, including randomized controlled trials, prospective studies, and database reviews.
Key findings show that da Vinci robotic cases were 56% less likely to convert to open surgery versus laparoscopy, experienced 21% fewer blood transfusions versus laparoscopy and 75% versus open, and had 10% fewer 30-day postop complications versus laparoscopy and 44% versus open. Patients also experienced shorter hospital stays, though operative times were longer than both traditional approaches.
Intuitive (ISRG) reported strong financial results for Q3 2024. Key highlights include:
- Worldwide da Vinci procedures grew 18% year-over-year
- 379 da Vinci surgical systems placed, up from 312 in Q3 2023
- Installed base increased 15% to 9,539 systems
- Revenue rose 17% to $2.04 billion
- GAAP net income of $565 million ($1.56 per diluted share)
- Non-GAAP net income of $669 million ($1.84 per diluted share)
The company saw growth in da Vinci procedure volume and system placements. Instruments and accessories revenue increased 18%, while systems revenue grew significantly. Intuitive ended the quarter with $8.31 billion in cash and investments.
Jupiter Endovascular, a medical technology startup, has exited stealth mode with $21 million in new financing to fund a pivotal trial for Pulmonary Embolism. The company is developing a new class of endovascular procedures using Endoportal Control™ technology, which aims to bring the precision of direct surgical access to catheter-based interventions. Carl J. St. Bernard has been appointed as CEO, bringing over 30 years of experience in the life sciences industry.
The funding round, led by Sonder Capital with participation from strategic investors, will support the upcoming pivotal trial and development of additional clinical applications. Jupiter's technology addresses limitations in catheter-based therapies by providing stability and control within complex cardiovascular anatomies, potentially revolutionizing treatment for millions of patients worldwide.
Neptune Medical, a medical device innovator, has announced a successful $97 million Series D financing and the spinout of its subsidiary, Jupiter Endovascular. The financing round saw significant participation from Sonder Capital and Olympus of the Americas, along with other existing and new investors. This strategic move allows Neptune Medical to focus on gastrointestinal robotics, while Jupiter Endovascular will concentrate on its novel endovascular technology platform.
The financing will strengthen Neptune Medical's position in the GI space, as evidenced by the recent appointment of Dr. Fred Moll, a medical robotics pioneer, as Chairman of the Board. Both companies aim to lead innovation in their respective specialties, with Neptune pushing boundaries in GI robotics and Jupiter revolutionizing endovascular therapies.
Intuitive (NASDAQ:ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has appointed its President David J. Rosa to the company's Board of Directors, effective July 24, 2024. Rosa joins CEO Gary S. Guthart as one of two Intuitive executives on the Board. With nearly 27 years at Intuitive, Rosa has held leadership positions across multiple functions and currently oversees the company's business unit, quality, regulatory, manufacturing, and commercial operations.
Rosa's appointment expands the Board from eleven to twelve directors, adding his deep operational experience to complement Guthart's focus on enterprise strategy. This move aims to balance strategy and operations at the Board level, enhancing Intuitive's stewardship.
Intuitive (Nasdaq: ISRG) reported strong Q2 2024 financial results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew approximately 17% compared to Q2 2023. The company placed 341 da Vinci surgical systems, including 70 da Vinci 5 systems, bringing the total installed base to 9,203 systems, a 14% increase year-over-year.
GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, while non-GAAP net income was $641 million, or $1.78 per diluted share. Instruments and accessories revenue increased by 16% to $1.24 billion, driven by procedure volume growth. The company ended Q2 with $7.68 billion in cash, cash equivalents, and investments.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
What is Intuitive Surgical Inc.?
What is the da Vinci Surgical System?
How many da Vinci systems are installed globally?
What recent achievements has Intuitive Surgical announced?
Are there different models of the da Vinci system?
What is the company's focus regarding patient care?
Where is Intuitive Surgical headquartered?
Does Intuitive Surgical offer training for its systems?
How can I get more information about Intuitive Surgical's financial performance?
What is the significance of the da Vinci 5 system?
